Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921259 | 1.00 | FFAR1 (0.44) | FFAR1HPGDCD274ANO1MRGPRX4 | |
| SCHEMBL13222719 | 0.90 | FFAR1 (0.36) | FFAR1HPGDCD274FFAR4SCN3A | |
| SCHEMBL3053045 | 0.83 | FFAR1 (0.44) | FFAR1HPGDPOLB | |
| SCHEMBL13222684 | 0.83 | FFAR1 (0.44) | FFAR1HPGDPOLB | |
| SCHEMBL18940278 | 0.82 | FFAR1 (0.41) | FFAR1HPGDFFAR4SCN3APOLB | |
| SCHEMBL18940277 | 0.77 | FFAR1 (0.42) | FFAR1HPGDANO1FFAR4SCN3A | |
| SCHEMBL18940272 | 0.77 | FFAR1 (0.46) | FFAR1SCN3A | |
| SCHEMBL18940279 | 0.77 | FFAR1 (0.46) | FFAR1SCN3A | |
| SCHEMBL9903728 | 0.75 | SMN1; SMN2 (0.38) | FFAR1HPGDPOLB | |
| SCHEMBL29423934 | 0.74 | FFAR1 (0.35) | FFAR1HPGDFFAR4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399507-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2215068-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR55 | FFAR1 19/4885HPGD 3191/4885CD274 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.